Recommended Topic Related To:

Metastron

"The U.S. Food and Drug Administration announced today that injectable drugs used in total parenteral nutrition (TPN) in critical shortage will be imported into the United States and available to patients this week.

TPN is an intravenous"...

Metastron

METASTRON™
(strontium-89 chloride) Injection

DRUG DESCRIPTION

Metastron is a sterile, non-pyrogenic, aqueous solution of Strontium-89 Chloride for intravenous administration. The solution contains no preservative.

Each milliliter contains:

Strontium Chloride 10.9 -22.6 mg
Water for Injection q.s. to 1 mL

The radioactive concentration is 37 MBq/mL, 1 mCi/mL, and the specific activity is 2.96-6.17 MBq/mg, 80-167 μCi/mg at calibration. The pH of the solution is 4 -7.5.

Physical Characteristics

Strontium-89 decays by beta emission with a physical half-life of 50.5 days. The maximum beta energy is 1.463 MeV (100%). The maximum range of β-from Strontium-89 in tissue is approximately 8 mm.

Radioactive decay factors to be applied to the stated value for radioactive concentration at calibration, when calculating injection volumes at the time of administration, are given in Table 1.

Table 1: Decay of Strontium-89

Day* Factor Day* Factor
-24 1.39 +6 0.92
-22 1.35 +8 0.90
-20 1.32 +10 0.87
-18 1.28 +12 0.85
-16 1.25 +14 0.83
-14 1.21 +16 0.80
-12 1.18 +18 0.78
-10 1.15 +20 0.76
-8 1.12 +22 0.74
-6 1.09 +24 0.72
-4 1.06 +26 0.70
-2 1.03 +28 0.68
0=calibration 1.00    
* Days before (-) or after (+) the calibration date stated on the vial.

Last reviewed on RxList: 1/24/2014
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.